Age-related disease play Unity planning IPO

Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho.

Unity's lead candidates target senescent cells to treat age-related diseases (see BioCentury, Oct. 31, 2016)...